New scan could spot breast cancer markers without a needle

NCT ID NCT05412446

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new imaging agent called 99mTc-ADAPT6 in 30 women with breast cancer that had spread to lymph nodes. The agent is designed to attach to HER2 proteins on cancer cells, allowing doctors to see them on a SPECT scan. The goal was to see if the scan results matched standard biopsy tests for HER2 status. If it works, this could offer a less invasive way to check HER2 levels in tumors and lymph nodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Technetium-99m-labelled ADAPT6 (99mTc-ADAPT6)
What this could lead to: If successful, this imaging method could help doctors see HER2 levels in breast cancer without needing a biopsy, guiding treatment decisions.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to all patients. The imaging agent may not match biopsy results perfectly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER FEMALE

Contacts and locations

Locations

Tomsk NRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.